Ryzneuta market set for growth as cancer supportive care demand rises
The Ryzneuta market is projected to expand through 2035 as cancer cases climb, chemotherapy use remains high and demand grows for long-acting supportive care drugs. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.
Why it matters: - Ryzneuta is part of the growing market for oncology supportive care, where preventing chemotherapy-related infection risk can affect treatment continuity and patient outcomes. - Rising global cancer incidence is increasing demand for therapies that help patients tolerate chemotherapy and avoid hospitalization. - The market outlook also reflects broader healthcare shifts toward outpatient cancer care and longer-acting biologic treatments.
What happened: - The Business Research Company published a 2026 global market report on the Ryzneuta market with forecasts through 2035. - The report identifies Ryzneuta, also known as efbemalenograstim alfa, as a long-acting granulocyte colony-stimulating factor used to lower infection risk in adults receiving chemotherapy for non-myeloid cancers. - The report says North America held the largest market share in 2025, while Asia-Pacific is projected to be the fastest-growing region.
The details: - The market’s historical growth is tied to more chemotherapy treatments, wider use of colony-stimulating factors, stronger oncology supportive care protocols, more hospital-based cancer treatment and greater awareness of neutropenia risk. - The forecast period is expected to be driven by long-acting biologic drug development, demand for outpatient cancer care, personalized oncology approaches, lower hospitalization rates and reimbursement support for oncology biologics. - Key trends expected in the period include broader use of long-acting G-CSF therapies, a sharper focus on chemotherapy support care, more infection-risk reduction strategies, improved treatment outcomes and better patient convenience and adherence. - Ryzneuta stimulates neutrophil production, helping the immune system fight infection during chemotherapy-induced neutropenia. - The report says cancer prevalence is a major growth driver for the market. - The World Health Organization projected in February 2024 that new cancer cases would rise from about 20 million in 2022 to more than 35 million by 2050, a 77% increase. - The report covers Asia-Pacific, Western and Eastern Europe, North America, South America, the Middle East and Africa. - The company also said its 2026 reports now include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis. - Download a free sample of the report. - View the full report.
Between the lines: - The market thesis points to a niche drug category benefiting from broad oncology trends rather than from a single product-specific catalyst. - Growth in outpatient care and efforts to cut hospital stays suggest buyers want therapies that are simpler to use and easier to fit into modern cancer treatment workflows. - The regional split signals a mature commercial base in North America and a faster expansion runway in Asia-Pacific.
What's next: - The report expects continued demand for long-acting G-CSF therapies as cancer care becomes more ambulatory and prevention-focused. - Reimbursement policy, adoption of biologics and regional healthcare investment will likely shape the pace of market growth through 2035. - The company is offering additional report access and analyst contact points for potential buyers and market research customers.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Market Forecast Reports
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.